Oncology (hepatic)

We focus on establishing an imaging biomarker for hepato-cellular carcinoma in the context of cirrhosis. The mixed modality technique of PET-MR currently holds the most promise in this regard.

HTML
Overview

Liver cirrhosis is characterized by tissue fibrosis & the conversion of normal liver architecture into structurally abnormal nodules which frequently become malignant as in the case of hepatocellular carcinoma.

Presently, CT & MR are used to detect & characterize hepatocellular carcinoma (HCC) nodules in liver cirrhosis. However, CTMR diagnostic accuracy is limited because both detection techniques rely on nodule vascularity. 

Consequently, we aim to establish an imaging biomarker which allows early & accurate detection & staging of HCC nodules before liver transplantation, as well as accurate differentiation of HCC nodules deserving treatment, from dysplastic & regenerative nodules which simply require imaging follow up. 

Integrated PETMR (PET-MR) with 11C-acetate could provide increased diagnostic accuracy in HCC nodule detection & characterization.

 

 

Current projects
Completed projects – more info to come.

 

Funding organisations & groups

More info to come.